While anti‐VEGF therapy in a preclinical cancer model eradicated myeloid‐derived suppressor cells (MDSCs), remaining T cells triggered the infiltration of additional myeloid cells through the IL‐17 pathway (Chung et al, 2013). The gene discussed is IL17A; the disease is cancer.